Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–56. https://doi.org/10.1002/ejhf.1858

Article  PubMed  Google Scholar 

Celik A, Ural D, Sahin A, et al. Trends in heart failure between 2016 and 2022 in Türkiye (TRends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages. Lancet Reg Health Eur. 2023;33: 100723. https://doi.org/10.1016/j.lanepe.2023.100723

Article  PubMed  PubMed Central  Google Scholar 

Page RL, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32-69. https://doi.org/10.1161/CIR.0000000000000426

Article  CAS  PubMed  Google Scholar 

Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1–167. https://doi.org/10.1016/j.cardfail.2022.02.010

Ackman ML, Campbell JB, Buzak KA, Tsuyuki RT, Montague TJ, Teo KK. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother. 1999;33(6):674–9. https://doi.org/10.1345/aph.18283

Article  CAS  PubMed  Google Scholar 

Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465–92. https://doi.org/10.1007/s10741-021-10135-4

Article  PubMed  Google Scholar 

Hu W, Tong J, Kuang X, Chen W, Liu Z. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel. Medicine (Baltimore). 2018;97(3): e9638. https://doi.org/10.1097/MD.0000000000009638

Article  CAS  PubMed  Google Scholar 

Almufleh A, Ramirez FD, So D, et al. H2 receptor antagonists versus proton pump inhibitors in patients on dual antiplatelet therapy for coronary artery disease: a systematic review. Cardiology. 2018;140(2):115–23. https://doi.org/10.1159/000489165

Article  CAS  PubMed  Google Scholar 

Scott SA, Obeng AO, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89. https://doi.org/10.1517/17425255.2014.856883

Article  CAS  PubMed  Google Scholar 

Ai MY, Chen YZ, Kuo CL, Chang WL. A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients. Front Cardiovasc Med. 2024;11. https://doi.org/10.3389/fcvm.2024.1385318

Lee D, Kim JS, Kim BJ, Shin SY, Kim DB, Ahn HS. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Medicine. 2021;100(52): e27411. https://doi.org/10.1097/MD.0000000000027411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 694698. https://doi.org/10.3389/fphar.2021.694698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z

Article  PubMed  Google Scholar 

Adelborg K, Sundbøll J, Schmidt M, et al. Use of histamine H(2) receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study. Clin Epidemiol. 2018;10:521–30. https://doi.org/10.2147/CLEP.S162909

Article  PubMed  PubMed Central  Google Scholar 

Huang YH, Cai WK, Yin SJ, et al. Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study. Eur J Prev Cardiol. 2022;29(17):2281–2281. https://doi.org/10.1093/eurjpc/zwac226

Article  Google Scholar 

Juurlink DN, Dormuth CR, Huang A, et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS ONE. 2013;8(12): e84890. https://doi.org/10.1371/journal.pone.0084890

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larson SR, Vasbinder AL, Reding KW, et al. Histamine H(2) receptor antagonists and heart failure risk in postmenopausal women: the women’s health initiative. J Am Heart Assoc. 2022;11(5): e024270. https://doi.org/10.1161/JAHA.121.024270

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leary PJ, Tedford RJ, Bluemke DA, et al. Histamine H2 receptor antagonists, left ventricular morphology, and heart failure risk: the MESA study. J Am Coll Cardiol. 2016;67(13):1544–52. https://doi.org/10.1016/j.jacc.2016.01.045

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li ZH, Zhong WF, Qiu CS, et al. Association between regular proton pump inhibitors use and cardiovascular outcomes: a large prospective cohort study. Int J Cardiol. 2023:131567. https://doi.org/10.1016/j.ijcard.2023.131567

Oudit GY, Bakal JA, McAlister FA, Ezekowitz JA. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. Eur J Heart Fail. 2011;13(11):1211–5. https://doi.org/10.1093/eurjhf/hfr104

Article  CAS  PubMed  Google Scholar 

Rooney MR, Bell EJ, Alonso A, et al. Proton pump inhibitor use, hypomagnesemia and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. J Clin Gastroenterol. 2021;55(8):677–83. https://doi.org/10.1097/MCG.0000000000001420

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292–7. https://doi.org/10.1016/j.ijcard.2014.09.036

Article  PubMed  Google Scholar 

Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton-pump ınhibitor use and the risk of first-time ıschemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112(7):1084. https://doi.org/10.1038/ajg.2017.101

Article  CAS  PubMed  Google Scholar 

Yoshihisa A, Takiguchi M, Kanno Y, et al. Associations of acid suppressive therapy with cardiac mortality in heart failure patients. J Am Heart Assoc. 2017;6(5): e005110. https://doi.org/10.1161/JAHA.116.005110

Article  PubMed  PubMed Central  Google Scholar 

Nolde M, Bahls M, Friedrich N, et al. Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: a cross-sectional study. Pharmacotherapy. 2021;41(2):198–204. https://doi.org/10.1002/phar.2504

Article  CAS  PubMed  Google Scholar 

Smith CA, Ebrahimpour A, Novikova L, et al. Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: insights into the cardiovascular risk of proton pump inhibitors. Biochim Biophys Acta (BBA) - Gen Subj. 2022;1866(8):130149. https://doi.org/10.1016/j.bbagen.2022.130149

Article  CAS  Google Scholar 

Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25(22):2706. https://doi.org/10.3748/wjg.v25.i22.2706

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang XS, Cai WK, Wang P, et al. Histamine H2 receptor antagonist exhibited comparable all-cause mortality-decreasing effect as β-blockers in critically ill patients with heart failure: a cohort study. Front Pharmacol. 2023;14:1273640. https://doi.org/10.3389/fphar.2023.1273640

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levick SP. Histamine receptors in heart failure. Heart Fail Rev. 2022;27(4):1355–72. https://doi.org/10.1007/s10741-021-10166-x